drugset / Trial / NCT01631201

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

NCT01631201

Phase 2 Completed 82 enrolled ActivBiotics Pharma, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test the safety and effectiveness of an investigational antibiotic drug, rifalazil for the treatment of uncomplicated genital Chlamydia trachomatis infection. This study will examine the effects of 25 milligram of rifalazil compared with azithromycin 1 gram, which will be given as a single dose to women who have genital chlamydial infection.

Timeline

Start
2012-07
Primary completion
2013-03
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azithromycin Small molecule 1 g
Subject Rifalazil Small molecule 25 mg Oral